Pharming, in coordination with Novartis Pharmaceuticals, is recruiting patients for the NCT02435173 clinical trial evaluating an experimental treatment for APDS, a primary immune deficiency.
This study is designed to explore CDZ173 (leniolisib), an investigational selective APDS inhibitor, in patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI (APDS/p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency).
Pharming is looking for patients and healthcare professionals who are interested in learning more about APDS and leniolisib, the current study protocol (inclusion/exclusion criteria) and potentially participating in the current or future clinical trials.
Additional details of the study including open sites for enrollment are also available on Clinicaltrials.gov at https://clinicaltrials.gov/ct2/show/NCT02435173
By completing this form, you are agreeing to receive communications from Pharming Healthcare Inc, its affiliates, and their agents and representatives regarding clinical trials, APDS and Leniolisib. You may opt out at any time.
You must be 16 years of age or older to fill out this form.
This registration form is for Health Care Providers only.
If yes, please provide additional information on the genetic testing results:
Please check your information and try again
Return to form